1. Home
  2. SNTI vs SDEV Comparison

SNTI vs SDEV Comparison

Compare SNTI & SDEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

HOLD

Current Price

$0.42

Market Cap

31.5M

Sector

Health Care

ML Signal

HOLD

SDEV

Stablecoin Development Corporation Common Stock

N/A

Current Price

$1.13

Market Cap

33.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SNTI
SDEV
Founded
2016
N/A
Country
United States
United States
Employees
N/A
4
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.5M
33.1M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
SNTI
SDEV
Price
$0.42
$1.13
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$8.50
N/A
AVG Volume (30 Days)
292.5K
751.4K
Earning Date
05-06-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
77.31
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.42
$1.01
52 Week High
$2.88
$1.60

Technical Indicators

Market Signals
Indicator
SNTI
SDEV
Relative Strength Index (RSI) 24.51 N/A
Support Level N/A N/A
Resistance Level $1.02 N/A
Average True Range (ATR) 0.08 0.00
MACD -0.05 0.00
Stochastic Oscillator 4.14 0.00

Price Performance

Historical Comparison
SNTI
SDEV

About SNTI Senti Biosciences Inc.

Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).

About SDEV Stablecoin Development Corporation Common Stock

Stablecoin Development Corp is an on-chain holding company focused on long-duration participation in protocol-aligned digital asset ecosystems. The Company's initial digital asset focus is the Sky protocol ecosystem, with SKY as its core holding. Through staking and other on-chain activities, the Company seeks to generate protocol-level economic returns while maintaining rigorous governance and risk management oversight.

Share on Social Networks: